⌘K

Home/Filings/4/0001641172-25-018282

4//SEC Filing

Brown Regina 4

Accession 0001641172-25-018282

CIK 0001335105other

View on SEC.gov Company Profile

Filed

Jul 7, 8:00 PM ET

Accepted

Jul 8, 9:33 PM ET

Size

19.0 KB

Accession

0001641172-25-018282

Insider Transaction Report

Form 4

Period: 2025-06-30

LIXTE BIOTECHNOLOGY HOLDINGS, INC.LIXT

Director

Transactions

Award
Options to Purchase Common Stock
2025-06-30+10,000→ 10,000 total
Exercise: $0.91From: 2025-09-30Exp: 2030-06-30→ Common (10,000 underlying)
Award
Options to Purchase Common Stock
2025-06-30+12,600→ 12,600 total
Exercise: $0.91From: 2025-06-30Exp: 2030-06-30→ Common (12,600 underlying)

Holdings

Options to Purchase Common Stock
Exercise: $7.45From: 2022-06-30Exp: 2027-06-30→ Common (10,000 underlying)
10,000
Options to Purchase Common Stock
Exercise: $30.30From: 2021-06-30Exp: 2026-06-30→ Common (10,000 underlying)
10,000
Options to Purchase Common Stock
Exercise: $28.00From: 2021-05-11Exp: 2026-05-11→ Common (25,000 underlying)
25,000
Options to Purchase Common Stock
Exercise: $1.21From: 2025-03-31Exp: 2030-03-31→ Common (9,508 underlying)
9,508
Options to Purchase Common Stock
Exercise: $1.30From: 2024-09-30Exp: 2029-09-30→ Common (6,269 underlying)
6,269
Options to Purchase Common Stock
Exercise: $5.88From: 2023-06-30Exp: 2028-06-30→ Common (10,000 underlying)
10,000
Options to Purchase Common Stock
Exercise: $2.33From: 2025-01-20Exp: 2030-01-20→ Common (4,924 underlying)
4,924
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (10,000 underlying)
10,000
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (4,904 underlying)
4,904

Footnotes (2)

[F1]Effective June 30, 2025, the reporting person was granted stock options to purchase an aggregate of 10,000 shares vesting in eight equal installments on the last day of each subsequent quarter until fully vested with vesting to start on September 30, 2025.
[F2]Effective June 30, 2025 the reporting person was granted stock options in aggregate of 12,600 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Documents

1 file

4
ownership.xmlPrimary

Issuer

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

CIK 0001335105

Entity typeother

Related Parties

1

filerCIK 0001862089

Filing Metadata

Form type: 4
Filed: Jul 7, 8:00 PM ET
Accepted: Jul 8, 9:33 PM ET
Size: 19.0 KB

View on SEC.gov